- VU0364770
-
- $31.00 / 10mg
-
2025-09-18
- CAS:61350-00-3
- Min. Order:
- Purity: 99.66%
- Supply Ability: 10g
|
| | VU 0364770 Basic information |
| Product Name: | VU 0364770 | | Synonyms: | VU 0364770;2-PyridinecarboxaMide, N-(3-chlorophenyl)-;N-(3-Chlorophenyl)picolinamide;N-(3-chlorophenyl)pyridine-2-carboxamide;VU 0364770 100MG;VU0364770;VU-0364770;VU 0364770 USP/EP/BP;SKL856 | | CAS: | 61350-00-3 | | MF: | C12H9ClN2O | | MW: | 232.67 | | EINECS: | | | Product Categories: | Aromatics, Heterocycles;Inhibitors | | Mol File: | 61350-00-3.mol |  |
| | VU 0364770 Chemical Properties |
| Melting point | 81-83 °C | | Boiling point | 293.6±20.0 °C(Predicted) | | density | 1.341±0.06 g/cm3(Predicted) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | DMF: 30 mg/ml; DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml; DMSO: 25 mg/ml; Ethanol: 5 mg/ml | | form | Powder | | pka | 11.24±0.70(Predicted) | | color | Light yellow to yellow |
| | VU 0364770 Usage And Synthesis |
| Uses | N-(3-Chlorophenyl)-2-pyridinecarboxamide shows positive allosteric modulation at the mGlu4 receptors in combination with other antagonists resulting in treatment for the neurodegenerative Parkinson’s disease (1). | | in vivo | VU0364770 exhibits suitable pharmacokinetic properties for systemic dosing in animal models. After intravenous administration, VU0364770 is rapidly clears from the systemic circulation (165 ml/min/kg) and exhibits a volume of distribution of 2.92 L/kg. VU0364770 is a highly protein-bound ligand displaying free fractions of 2.7 and 1.8% in human and rat plasma, respectively. VU0364770 also shows an improved pharmacokinetic profile relative to previously reported mGlu4 PAMs with enhanced central penetration and a total brain-to-plasma ratio of more than 1 after systemic administration of a 10 mg/kg dose. VU0364770 produces a dose-dependent reversal of haloperidol-induced catalepsy. VU0364770 dose-dependently reverses haloperidol (0.75 mg/kg)-induced catalepsy in rats, significant at doses of 10 to 56.6 mg/kg, after subcutaneous dosing (F6,69=8.04; p<0.001)[1]. | | IC 50 | Rat mGlu4: 290 nM (EC50); Human mGlu4: 1.1 μM (EC50); mGlu6: 6.8 μM (EC50); mGlu5: 17.9 μM (EC50) |
| | VU 0364770 Preparation Products And Raw materials |
|